About

 

Management

Ole Thastrup

Chief Executive Officer

Board member and CEO of 2cureX AB and 2cureX A/S

Ole Thastrup (B. 1953) is co-founder and CEO of 2cureX. He has been a board member and CEO of 2cureX since 2006.

Ole holds a MS in Pharmacy and a PhD in Pharmacology and Medicinal Chemistry. Ole is also Professor at the University of Copenhagen. Prior to 2cureX Ole was Head of Carlsberg Biosector where he was responsible for Carlsberg's biomedical research. Before that, Ole was the scientific founder and Chief Scientific Officer of BioImage A/S (now Thermo Fischer BioImage) that was spun out of Novo Nordisk A/S. Ole is inventor of several families of globally issued patents. He had advised several venture funds and is member of granting institutions (e.g. Novo Nordisk Foundation).

2cureX share ownership and warrants
3 778 304 shares via own company
Other board assignments
OT311 APS
Independense
Affiliated to management, the company, and major shareholders

Maarten van der Linden

Chief Business Officer

Maarten van der Linden (B. 1969) joined 2cureX in 2017.

Maarten has 15 years of experience in the international Life Science and diagnostic industry. Maarten was recently Senior Director of Marketing for the EMEA region at Abbott Laboratories where he in three consecutive years outperformed the diagnostic market growth with a focus on Molecular Diagnostics and especially the oncology market. Before that, Maarten was Senior Director of Global marketing at Agilent Technologies in Denmark and Regional Business Manager for new Products at Merck, Sharp & Dohme covering multiple disease areas, including oncology. Maarten holds an Executive MBA Henley Business School, UK.

2cureX share ownership and warrants
7464 shares
46 662 warrants

Carit J. Andersen

Chief Financial Officer

Carit Jacques Andersen (B. 1964) joined 2cureX in 2019 as CFO.

Carit holds an M.Sc. in Business Administration. Carit has over 25 years of experience in financial controlling and has previously been active in both the private and public sector. Previous assignments include the role as CFO at AstraZeneca A/S.

2cureX share ownership and warrants
11 715 shares

Henrik Harling

Chief Medical Officer

Henrik Harling (B. 1953) joined 2cureX in 2019 as CMO.

Henrik is experienced surgeon within colorectal cancer. He is one of the founders of the Danish Colorectal Cancer Group (DCCG). Harling was Chairman from 1994 to 2010. DCCG is setting guidelines for colorectal cancer treatment and involved in deciding on implementation of new diagnostic technologies in Denmark.

2cureX share ownership and warrants
23 430 shares

Grith Hagel

Head of Project Management

Grith Hagel (B. 1959) is co-founder of 2cureX in 2006.

Grith holds a degree of Biomedical Laboratory Science.

Grith has a comprehensive experience in developing and running drug screening campaigns. Grith is the inventor of several patents on advanced cell-based, high throughput screening technologies. Grith Hagel was co-founder of BioImage A/S that was spun-out of Novo Nordisk. She was responsible for the development of functional cell-based assays, and for their transfer to partners like Amersham plc (now GE Healthcare).

2cureX share ownership and warrants
619 735 shares

Jürgen Kupper

Managing director (2cureX GmbH)

Jürgen Kupper (B. 1965) joined 2cureX in 2015.

He began his career at Evotec AG in 1999. Jürgen’s previous experience include COO of Evotec Technologies, Product Leader for Live Cell Imaging at PerkinElmer and managing director of the diagnostic center at the University Medical Center Hamburg-Eppendorf (UKE). Jürgen holds a Ph.D. in Biophysics from Brandeis University, USA.

2cureX share ownership and warrants
150 501 warrants


Subscription for 2cureX News and Press Releases

Language News type
Your information

Data storage policy

Contact information

2cureX, Fruebjergvej 3, 2100 Copenhagen Ø, Denmark| Phone: +45 2211 5399| E-mail: info@2curex.com

Privacy Policy | Imprint